Advanced liver fibrosis in NAFLD and antiplatelet therapy: a meta-analysis

Recent studies have found the new use of antiplatelet agents for antifibrotic benefits in NAFLD, but human studies are still limited. The authors of this meta-analysis aimed to combine the findings.....
PUBLISHED IN: Indian J Gastroenterol 2022

Commentary

Recent studies have found the new use of antiplatelet agents for antifibrotic benefits in NAFLD, but human studies are still limited.

The authors of this meta-analysis aimed to combine the findings of existing relevant studies to investigate the effects of antiplatelet therapy in reducing or preventing advanced liver fibrosis in patients with NAFLD.

Four studies involving 2,593 patients with NAFLD were included in this meta-analysis. Preliminary evidence from this meta-analysis suggests a protective association between antiplatelet therapy and the prevalence of advanced liver fibrosis in patients with NAFLD.

Share the article
Dr. D. Beard

Dr. D. Beard

Articles: 189

Leave a Reply

Your email address will not be published.

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES